Clark Lawrence Anderson
Physician at 9 Ave, Columbus, OH
License number
Colorado 16972
Issued Date
Apr 13, 1971
Renew Date
May 31, 1991
Expiration Date
May 31, 1991
Type
Physician
Address
Address
480 W 9Th Ave, Columbus, OH 43210
Professional information
Bifunctional And Heteroantibodies Specific For The High Affinity Fc Receptor For Immunoglobulin G On Human Mononuclear Phagocytes
US Patent:
5635600, Jun 3, 1997
Filed:
Dec 27, 1994
Appl. No.:
8/364435
Inventors:
Michael W. Fanger - Lebanon NH
Paul M. Guyre - Hanover NH
Clark L. Anderson - Columbus OH
Paul M. Guyre - Hanover NH
Clark L. Anderson - Columbus OH
Assignee:
Trustees of Dartmouth College - Hanover NH
International Classification:
C07K 1618, C07K 1646
US Classification:
5303873
Abstract:
Monoclonal antibodies which react specifically to Fc receptor of human effector cells IgG are disclosed. Binding of the antibodies to the receptor is not blocked by human immunoglobulin G. The antibodies are useful for targeting human effector cells (e. g. macrophages) against a target cell (e. g. a cancer cell, an infectious agent, etc. ) For this purpose, bifunctional antibodies or heteroantibodies can be constructed containing the binding region derived from an anti-Fc receptor antibody and the binding region of a target-specific antibody. Targeted effector cells can be used to kill target cells by cell mediated antibody dependent cytolysis.
Methods For Use Of Monoclonal Antibodies Specific For The High Affinity Fc Receptor For Immunoglobulin G
US Patent:
6096311, Aug 1, 2000
Filed:
Jun 2, 1997
Appl. No.:
8/866982
Inventors:
Michael W. Fanger - Lebanon NH
Paul M. Guyre - Hanover NH
Clark L. Anderson - Columbus OH
Paul M. Guyre - Hanover NH
Clark L. Anderson - Columbus OH
Assignee:
Medarex - Annandale NJ
International Classification:
A61K 39395, C12P 2108, C12K 1600
US Classification:
4241361
Abstract:
Monoclonal antibodies which react specifically to Fc receptor of human effector cells are disclosed. Binding of the antibodies to the receptor is not blocked by human immunoglobulin G. The antibodies are useful for targeting human effector cells (e. g. macrophages) against a target cell (e. g. a cancer cell, an infectious agent, etc. ) For this purpose, bifunctional antibodies or heteroantibodies can be constructed containing the binding region derived from an anti-Fc receptor antibody and the binding region of a target-specific antibody. Targeted effector cells can be used to kill target cells by cell mediated antibody dependent cytolysis.
Monoclonal Antibodies To Fc Receptors For Immunoglobulin G On Human Mononuclear Phagocytes
US Patent:
4954617, Sep 4, 1990
Filed:
Jul 1, 1987
Appl. No.:
7/069412
Inventors:
Michael W. Fanger - Lebanon NH
Paul M. Guyre - Hanover NH
Clark L. Anderson - Columbus OH
Paul M. Guyre - Hanover NH
Clark L. Anderson - Columbus OH
Assignee:
Trustees of Dartmouth College - Hanover NH
International Classification:
A61K 39395, C07K 1514, C12N 500
US Classification:
530387
Abstract:
Monoclonal antibodies specific for the high affinity (72 K. D. ) F. sub. c receptor on human monocytes are diclosed. The monoclonal antibodies do not block normal IgG binding to the receptor.